A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-02-17
Adverse events
Grade 1 Neutropenia — outcome: UNKNOWN; onset 2023-07-17 (study day 140); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 154); relationship: N
Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-30 (study day 276); relationship: not assessed; serious criteria: life-threatening
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-01-12 (study day 319); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-21 (study day 328); relationship: Y
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-01 (study day 339); relationship: N
Data queries
No data queries.